These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 22651810)
1. Validation of the Japanese version of the EORTC hepatocellular carcinoma-specific quality of life questionnaire module (QLQ-HCC18). Mikoshiba N; Tateishi R; Tanaka M; Sakai T; Blazeby JM; Kokudo N; Koike K; Kazuma K Health Qual Life Outcomes; 2012 May; 10():58. PubMed ID: 22651810 [TBL] [Abstract][Full Text] [Related]
2. International cross-cultural field validation of an European Organization for Research and Treatment of Cancer questionnaire module for patients with primary liver cancer, the European Organization for Research and Treatment of Cancer quality-of-life questionnaire HCC18. Chie WC; Blazeby JM; Hsiao CF; Chiu HC; Poon RT; Mikoshiba N; Al-Kadhimi G; Heaton N; Calara J; Collins P; Caddick K; Costantini A; Vilgrain V; Trinquart L; Chiang C; Hepatology; 2012 Apr; 55(4):1122-9. PubMed ID: 22105642 [TBL] [Abstract][Full Text] [Related]
3. Development and Validation of the Simplified Chinese Version of EORTC QLQ-HCC18 for Patients with Hepatocellular Carcinoma. Yang Z; Wan C; Li W; Cun Y; Meng Q; Ding Y; Chen P Cancer Invest; 2015; 33(8):340-6. PubMed ID: 26046473 [TBL] [Abstract][Full Text] [Related]
4. The association of liver function and quality of life of patients with liver cancer. Li L; Mo F; Hui EP; Chan SL; Koh J; Tang NLS; Yu SCH; Yeo W BMC Gastroenterol; 2019 May; 19(1):66. PubMed ID: 31046687 [TBL] [Abstract][Full Text] [Related]
5. Psychometric validation of the EORTC QLQ-HCC18 in patients with previously treated unresectable hepatocellular carcinoma. Serrano D; Podger L; Barnes G; Song J; Tang B Qual Life Res; 2022 Mar; 31(3):937-950. PubMed ID: 34518988 [TBL] [Abstract][Full Text] [Related]
6. Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18. Blazeby JM; Currie E; Zee BC; Chie WC; Poon RT; Garden OJ; Eur J Cancer; 2004 Nov; 40(16):2439-44. PubMed ID: 15519517 [TBL] [Abstract][Full Text] [Related]
7. Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data. Li L; Mo FK; Chan SL; Hui EP; Tang NS; Koh J; Leung LK; Poon AN; Hui J; Chu CM; Lee KF; Ma BB; Lai PB; Chan AT; Yu SC; Yeo W BMC Cancer; 2017 Jan; 17(1):8. PubMed ID: 28052758 [TBL] [Abstract][Full Text] [Related]
8. Status of inflammation in relation to health related quality of life in hepatocellular carcinoma patients. Li L; Chan SL; Mo F; Hui EP; Koh J; Chan AK; Tang NL; Chu CM; Hui J; Lee KF; Yu S; Yeo W Qual Life Res; 2019 Sep; 28(9):2597-2607. PubMed ID: 31037590 [TBL] [Abstract][Full Text] [Related]
9. A prospective study to validate the Polish language version of the European Organisation for Research and Treatment of Cancer (EORTC) Colorectal Liver Metastases (QLQ-LMC21) module. Paradowska D; Bereza K; Sanna B; Kucharska E; Tomaszewska IM; Dudkiewicz Z; Skotnicki P; Bottomley A; Tomaszewski KA Eur J Oncol Nurs; 2017 Aug; 29():148-154. PubMed ID: 28578847 [TBL] [Abstract][Full Text] [Related]
10. A Prospective Evaluation of the Reliability and Utility of Quality of Life Measures in Patients With Hepatocellular Carcinoma. Kim GA; Kim HI; Chang S; An J; Lee D; Lee HC; Han S; Shim JH Am J Clin Oncol; 2019 Jul; 42(7):555-563. PubMed ID: 31135382 [TBL] [Abstract][Full Text] [Related]
11. Summary scores captured changes in subjects' QoL as measured by the multiple scales of the EORTC QLQ-C30. Phillips R; Gandhi M; Cheung YB; Findlay MP; Win KM; Hai HH; Yang JM; Lobo RR; Soo KC; Chow PK J Clin Epidemiol; 2015 Aug; 68(8):895-902. PubMed ID: 25843232 [TBL] [Abstract][Full Text] [Related]
12. Translation and validation of Sinhala version of modified EORTC QLQ-OH15 in oral cancer patients who receive radiotherapy with or without chemotherapy in Sri Lanka. Kosgallana S; Jayasekara P; Abeysinghe P; Hjermstad M; Lalloo R BMC Oral Health; 2022 Aug; 22(1):359. PubMed ID: 35986341 [TBL] [Abstract][Full Text] [Related]
13. Reliability and validity of the Amharic version of European Organization for Research and Treatment of cervical Cancer module for the assessment of health related quality of life in women with cervical cancer in Addis Ababa, Ethiopia. Araya LT; Gebretekle GB; Gebremariam GT; Fenta TG Health Qual Life Outcomes; 2019 Jan; 17(1):13. PubMed ID: 30642359 [TBL] [Abstract][Full Text] [Related]
14. A brief instrument to measure health-related quality-of-life in patients with bone metastasis: validation of the German version of Bone Metastases Quality-of-Life-10 (BOMET-QoL-10). Marschner N; Wilke J; Reschke D; Kaiser F; Schmoor C; Grugel R; Boller E J Med Econ; 2018 Sep; 21(9):920-929. PubMed ID: 29874105 [TBL] [Abstract][Full Text] [Related]
15. Reliability and Validity of Amharic Version of EORTC QLQ-C 30 Questionnaire among Gynecological Cancer Patients in Ethiopia. Ayana BA; Negash S; Yusuf L; Tigeneh W; Haile D PLoS One; 2016; 11(6):e0157359. PubMed ID: 27304066 [TBL] [Abstract][Full Text] [Related]
16. Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observational field study. Koller M; Shamieh O; Hjermstad MJ; Hornslien K; Young T; Chalk T; Ioannidis G; Harle A; Johnson CD; Tomaszewski KA; Serpentini S; Pinto M; van der Weijst L; Janssens A; Morag O; Chie WC; Arraras JI; Pompili C; Jungraithmayr W; Hechtner M; Katsochi D; Müller K; Gräfenstein L; Schulz C; Bottomley A; ; ; Lancet Oncol; 2020 May; 21(5):723-732. PubMed ID: 32213338 [TBL] [Abstract][Full Text] [Related]
17. Validation and reliability of the Dutch version of the EORTC QLQ-BLM30 module for assessing the health-related quality of life of patients with muscle invasive bladder cancer. Ripping TM; Rammant E; Witjes JA; Aaronson NK; van Hemelrijck M; van Hoogstraten LMC; ; Kiemeney LA; Aben KKH Health Qual Life Outcomes; 2022 Dec; 20(1):171. PubMed ID: 36581934 [TBL] [Abstract][Full Text] [Related]
18. Depressive symptoms after treatment in hepatocellular carcinoma survivors: prevalence, determinants, and impact on health-related quality of life. Mikoshiba N; Miyashita M; Sakai T; Tateishi R; Koike K Psychooncology; 2013 Oct; 22(10):2347-53. PubMed ID: 23686523 [TBL] [Abstract][Full Text] [Related]
19. Differences in health-related quality of life between European and Asian patients with hepatocellular carcinoma. Chie WC; Blazeby JM; Hsiao CF; Chiu HC; Poon RT; Mikoshiba N; Al-Kadhim G; Heaton N; Calara J; Collins P; Caddick K; Costantini A; Vilgrain V; Asia Pac J Clin Oncol; 2017 Oct; 13(5):e304-e311. PubMed ID: 27038366 [TBL] [Abstract][Full Text] [Related]
20. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]